Infectious Bacterial Diseases Research Unit Site Logo
ARS Home About Us Helptop nav spacerContact Us En Espanoltop nav spacer
Printable VersionPrintable Version     E-mail this pageE-mail this page
Agricultural Research Service United States Department of Agriculture
Search
  Advanced Search
 
Programs and Projects
Subjects of Investigation
 

Title: DNA VACCINES AGAINST TUBERCULOSIS

Authors
item Chacon, Ofelia - UNIV. OF NEBRASKA
item Bannantine, John

Submitted to: Book Chapter
Publication Type: Book / Chapter
Publication Acceptance Date: December 8, 2005
Publication Date: March 10, 2006
Citation: Chacon, O., Bannantine, J.P. 2006. Dna vaccines against tuberculosis. In: Thoen, C.O., Steele, J.H., Gilsdorf, M.J., editors. Mycobacterium Bovis: Infection in Animals and Humans. 2nd edition. Ames, IA: Blackwell Publishing. p. 285-304.

Interpretive Summary: This communication represents an invited book chapter. The content of this chapter is a comprehensive survey of work performed in the area of vaccine discovery and trials as it relates to tuberculosis, the number one killer among pathogenic bacteria. These findings are then briefly related to applicability in preventing other mycobacterial diseases such as Johne’s disease.

Technical Abstract: Since its early development more than two hundred years ago, vaccination has become one of the most effective measures to prevent infectious diseases. The use of vaccines is responsible for global eradication of smallpox and also for saving millions of human lives that otherwise would have been lost or severely impaired due to diseases such as polio, tetanus and measles, among others. An ideal vaccine should: (A) elicit long lasting protective immunity, preferably soon after its administration, without causing disease in the recipient or subsequent contacts, (B) allow detection of infected vs. immunized individuals without interfering with available diagnostic tests, (C) be cost effective and easy to produce in large quantities, (D) be easy to store and transport preserving its immunobiological properties under different environmental conditions, (E) be easy to administer to large populations, ideally in a single dose, without causing side effects, (F) be safe enough to be used in immunocompromised hosts, (G) have therapeutic potential and (H) be compatible with other vaccines so they can be administered simultaneously without interfering with each other’s effectiveness and safety. Additionally, consideration should be given to the different environments and societies in which the vaccine must be administered, since those factors will directly affect individual’s compliance with any proposed immunization regimen. This chapter reviews how DNA vaccines fare against these criteria in preventing tuberculosis.

   
 
 
Last Modified: 06/19/2013
ARS Home | USDA.gov | Site Map | Policies and Links 
FOIA | Accessibility Statement | Privacy Policy | Nondiscrimination Statement | Information Quality | USA.gov | White House